CClinicalTrials.gg
Sign In
Not yet recruitingNCT06863441Updated Mar 7, 2025

The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

An observational study in T-NK Cell Lymphoma, sponsored by Ruijin Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Ruijin Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.

Read the detailed description

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy.

02

Conditions studied

  • T-NK Cell Lymphoma

Browse trials for

Keywords

  • PET/CT
  • Granzyme B
  • immunotherapy
03

In context

Lymphoma

5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.

This study's planned enrollment of 50 is below the median of 136 across 625 observational studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Ruijin Hospital is the lead sponsor of 635 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chinese patient with pathologically confirmed T-NK cell lymphoma

Inclusion criteria

  1. Age > 18 years, regardless of gender.
  2. Histopathologically confirmed diagnosis of T-NK cell lymphoma.
  3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
  4. Availability of complete clinicopathological and follow-up data.
  5. Signed and dated informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received anti-tumor therapy.
  2. Patients with a history of other malignancies.
  3. Incomplete clinical information or imaging data.
  4. Concurrent other malignant tumors.
  5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
  6. Poor compliance.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • patients diagnosed with T-NK cell lymphoma who will receive immunotherapy
06

What researchers measure

Primary outcomes

  1. Standardized uptake value (SUV)

    SUV of 68Ga-grazytracer uptake on PET/CT images for tumor lesions

    Time frame: Baseline and 7-10 days after treatment

Secondary outcomes

  1. Progress free suivival

    Progress free suivival

    Time frame: 3 years

  2. Overall survival

    Overall survival

    Time frame: 3 years

07

Study locations

1 site
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06863441
Lead sponsor
Ruijin Hospital
Responsible party
LI BIAO (chief physician, Ruijin Hospital) — Principal investigator
First posted
Mar 7, 2025
Start date
Mar 1, 2025 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 7, 2025

Study contacts

Xinyu Zhang
Contact
zhangxinyu76@126.com
15958022176

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lymphoma→

Other studies from this sponsor

Ruijin Hospital

Start the discussion